Protagonist Therapeutics (NASDAQ:PTGX) Sees Strong Trading Volume
Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) saw strong trading volume on Thursday . 898,218 shares were traded during trading, an increase of 342% from the previous session’s volume of 203,208 shares.The stock last traded at $13.65 and had previously closed at $13.21.
A number of research analysts recently issued reports on the company. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. HC Wainwright set a $73.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Stifel Nicolaus upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, ValuEngine upgraded VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $17.17.
The company has a debt-to-equity ratio of 0.07, a current ratio of 5.02 and a quick ratio of 5.02. The firm has a market cap of $319.36 million, a price-to-earnings ratio of -7.84 and a beta of 1.88. The business has a 50 day moving average of $11.69.
Hedge funds have recently bought and sold shares of the business. Bank of Montreal Can boosted its stake in Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock worth $139,000 after purchasing an additional 10,405 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of Protagonist Therapeutics by 75.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after acquiring an additional 8,450 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Protagonist Therapeutics by 94.3% during the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after acquiring an additional 12,819 shares in the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of Protagonist Therapeutics during the 1st quarter worth approximately $410,000. Finally, Northern Trust Corp raised its holdings in shares of Protagonist Therapeutics by 17.2% during the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after acquiring an additional 5,084 shares in the last quarter. Institutional investors and hedge funds own 64.40% of the company’s stock.
Protagonist Therapeutics Company Profile (NASDAQ:PTGX)
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.